Clinical Characteristics and Prognosis of Anti-AChR Positive Myasthenia Gravis Combined With Anti-LRP4 or Anti-Titin Antibody

Some patients have more then one antibody known to play a role in MG. The study involved 188 patients and examined their clinical characteristics, response to immunotherapy, and prognosis. The results showed that patients with anti-AChR positive MG combined with anti-Titin antibodies had more severe symptoms and faster disease progression compared to those with anti-AChR combined with anti-LRP4 antibodies or only anti-AChR antibodies. However, regardless of antibody status, all patients responded well to immunotherapy and had relatively good prognoses.